IN THE CLAIMS

1 (Currently Amended): ~~A brain protective agent comprising an~~ A compound which inhibits the activation of a gene by NF-κB ~~decoy~~.

2 (Currently Amended): The ~~brain protective agent according to Claim 1 for the brain disorder arising from encephalopathy~~ compound of Claim 1, which is a nucleic acid or a nucleic acid analog.

3 (Currently Amended): The ~~brain protective agent according to Claim 2 wherein the encephalopathy is a cerebrovascular accident~~ compound of Claim 1 which is a nucleic acid or nucleic acid analog which comprises the consensus sequence of the NF-κB bnding site.

4 (Currently Amended): The ~~brain protective agent according to Claim 2 wherein the brain disorder arising form encephalopathy is cerebral vasospasm associated with subarachnoid hemorrhage~~ compound of Claim 1 which is a nucleic acid or nucleic acid analog which comprises the base sequence of SEQ ID NO: 1.

5 (New): A method for treating a brain disorder comprising administering to a subject in need thereof an effective amount of a composition comprising:

a compound which inhibits the activation of a gene by NF-κB and

a carrier.

6 (New): The method of Claim 5, wherein said carrier is a liposome.

7 (New): The method of Claim 5, wherein said carrier is a cationic liposome.

8 (New): The method of Claim 5, wherein said carrier is a liposome comprising a membrane fusion promoter.

9 (New): The method of Claim 5, wherein said compound is a nucleic acid or a nucleic acid analog.

10 (New): The method of Claim 5, wherein said compound is a nucleic acid or nucleic acid analog which comprises the consensus sequence of the NF-κB bnding site.

11 (New): The method of Claim 5, wherein said compound is a nucleic acid or nucleic acid analog which comprises the base sequence of SEQ ID NO: 1.

12 (New): The method of Claim 5, wherein said compound is a double-stranded nucleic acid or nucleic acid analog.

13 (New): The method of Claim 5, wherein said compound is a cyclic nucleic acid or nucleic acid analog.

14 (New): The method of Claim 5, wherein said compound comprises an S-oligonucleotide, an oligonucleotide in which one or more methyl phosphate group(s) carrying no charge has (have) been substituted for the phosphodiester bond, an acylated oligonucleotide, or an alkylated oligonucleotide, comprising the base sequence of SEQ ID NO: 1.

15 (New): The method of Claim 5, wherein said compound comprises several units of a double-stranded nucleic acid or nucleic acid analog, which comprises the consensus sequence of the NF-κB bnding site.

16 (New): The method of Claim 5, wherein said composition is administered intracisternally.

17 (New): The method of Claim 5, wherein said composition is administered in a dose ranging from 10 to 10,000 nmoles.

18 (New): A liposome comprising a compound which inhibits the activation of a gene by NF-κB.

19 (New): The liposome of Claim 18 that comprises a cationic lipid.

20 (New): The liposome of Claim 18 that comprises a membrane-fusion promoter.

21 (New): The liposome of Claim 18 that comprises a large unilamellar vesicle (LUV) structure.

22 (New): The liposome of Claim 18 that comprises a multilamellar vesicle (MLV) structure.

23 (New): The liposome of Claim 18 that comprises a small unilamellar vesicle (SUV) structure.